Emily Bodnar’s score relies over the anticipation of important milestones for Agenus in the approaching calendar year, especially the prospective submitting of the Biologics License Application (BLA) for their guide drug candidate, botensilimab (bot). Agenus has dosed about 900 individuals with bot across various sound tumors, displaying a dedica